195 related articles for article (PubMed ID: 16455347)
21. Pemphigoid nodularis associated with psoriatic erythroderma: successful treatment with suplatast tosilate.
Teraki Y; Fukuda T
Br J Dermatol; 2008 Feb; 158(2):424-6. PubMed ID: 18047503
[No Abstract] [Full Text] [Related]
22. Individual cytokines contributing to asthma pathophysiology: valid targets for asthma therapy?
Chung KF
Curr Opin Investig Drugs; 2003 Nov; 4(11):1320-6. PubMed ID: 14758771
[TBL] [Abstract][Full Text] [Related]
23. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab.
Nowak D
Respir Med; 2006 Nov; 100(11):1907-17. PubMed ID: 16949266
[TBL] [Abstract][Full Text] [Related]
24. [Immunomodulation therapy for allergic asthma. What is already possible, what is to come?].
Taube C; Buhl R
Dtsch Med Wochenschr; 2008 Apr; 133(14):727-32. PubMed ID: 18363195
[TBL] [Abstract][Full Text] [Related]
25. Biologic immune modifiers: Trials and tribulations--are we there yet?
Ballow M
J Allergy Clin Immunol; 2006 Dec; 118(6):1209-15; quiz 1216-7. PubMed ID: 17157649
[TBL] [Abstract][Full Text] [Related]
26. The effects of suplatast tosilate treatment and prophylaxis on lung histopathology in a mouse model of chronic asthma.
Tuncel T; Karaman M; Ayyildiz ZA; Uysal P; Kiray M; Bagriyanik AH; Yilmaz O; Karaman O; Uzuner N
J Investig Med; 2014 Jan; 62(1):56-61. PubMed ID: 24113733
[TBL] [Abstract][Full Text] [Related]
27. Early intervention with suplatast tosilate for prophylaxis of pediatric atopic asthma: a pilot study.
Yoshihara S; Ono M; Yamada Y; Fukuda H; Abe T; Arisaka O
Pediatr Allergy Immunol; 2009 Aug; 20(5):486-92. PubMed ID: 19210644
[TBL] [Abstract][Full Text] [Related]
28. [Successful treatment of chronic eosinophilic pneumonia with suplatast tosilate].
Kusumoto H; Mizuno K; Yonemaru M; Nakano M; Ichinose Y; Toyama K
Nihon Kyobu Shikkan Gakkai Zasshi; 1997 May; 35(5):550-4. PubMed ID: 9234634
[TBL] [Abstract][Full Text] [Related]
29. Kimura's disease treated with suplatast tosilate and loratadine.
Ueda T; Arai S; Amoh Y; Katsuoka K
Eur J Dermatol; 2011; 21(6):1020-1. PubMed ID: 21914581
[No Abstract] [Full Text] [Related]
30. Suplatast tosilate alleviates nasal symptoms through the suppression of nuclear factor of activated T-cells-mediated IL-9 gene expression in toluene-2,4-diisocyanate-sensitized rats.
Mizuguchi H; Orimoto N; Kadota T; Kominami T; Das AK; Sawada A; Tamada M; Miyagi K; Adachi T; Matsumoto M; Kosaka T; Kitamura Y; Takeda N; Fukui H
J Pharmacol Sci; 2016 Mar; 130(3):151-8. PubMed ID: 26874672
[TBL] [Abstract][Full Text] [Related]
31. Interaction of suplatast tosilate (IPD) with chloride channels in human blood eosinophils: a potential mechanism underlying its anti-allergic and anti-asthmatic effects.
Agrawal DK; Cheng G; Kim MJ; Kiniwa M
Clin Exp Allergy; 2008 Feb; 38(2):305-12. PubMed ID: 18028459
[TBL] [Abstract][Full Text] [Related]
32. Suplatast tosilate inhibits late response and airway inflammation in sensitized guinea pigs.
Iijima H; Tamura G; Hsiue TR; Liu Y; Taniguchi H; Shirato K
Am J Respir Crit Care Med; 1999 Jul; 160(1):331-5. PubMed ID: 10390420
[TBL] [Abstract][Full Text] [Related]
33. Biologic therapies for the treatment of asthma.
Wagelie-Steffen AL; Kavanaugh AF; Wasserman SI
Clin Chest Med; 2006 Mar; 27(1):133-47, vii. PubMed ID: 16543058
[TBL] [Abstract][Full Text] [Related]
34. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.
Noga O; Hanf G; Brachmann I; Klucken AC; Kleine-Tebbe J; Rosseau S; Kunkel G; Suttorp N; Seybold J
J Allergy Clin Immunol; 2006 Jun; 117(6):1493-9. PubMed ID: 16751018
[TBL] [Abstract][Full Text] [Related]
35. Case 36-2007: a woman with rash, fever, and hypotension.
Mir MA; Khalil F
N Engl J Med; 2008 Mar; 358(13):1406; author reply 1406-7. PubMed ID: 18376447
[No Abstract] [Full Text] [Related]
36. Effect of suplatast tosilate, an antiallergic selective Th2 cytokine inhibitor, on acute eosinophilic myocarditis: a case report.
Umemoto S; Itagaki K; Kimura M; Itoh S; Tanaka M; Haraguchi M; Matsuzaki M
Heart Vessels; 2003 May; 18(2):100-2. PubMed ID: 12756607
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment of pediatric hypereosinophilic syndrome with suplatast tosilate.
Yamada Y; Yoshihara S; Arisaka O
Ann Allergy Asthma Immunol; 2007 Oct; 99(4):380-1. PubMed ID: 17941289
[No Abstract] [Full Text] [Related]
38. Suplatast tosilate for treating cutaneous mastocytosis.
Yasudo H; Ando T; Hiwatari M; Oka A
Pediatr Dermatol; 2015; 32(3):e118-9. PubMed ID: 25779849
[TBL] [Abstract][Full Text] [Related]
39. Effects of suplatast tosilate (IPD Capsules) on the production of active oxygen by neutrophils and of IL-8 by mononuclear cells.
Tohda Y; Kubo H; Haraguchi R; Iwanaga T; Fukuoka M
Int Immunopharmacol; 2001 Jun; 1(6):1183-7. PubMed ID: 11407312
[TBL] [Abstract][Full Text] [Related]
40. Inhibitory effect of azelastine hydrochloride and suplatast tosilate on airway responses in sensitized rats following exposure to antigen.
Hanashiro K; Tamaki N; Koga T; Nakamura M; Kinjoh K; Kosugi T
Int J Tissue React; 1997; 19(3-4):163-9. PubMed ID: 9506318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
